Jutta Deckert
Vice President, Research & Development Iksuda Therapeutics
Jutta Deckert has more than 20 years of industry experience in oncology drug development with a focus on translational medicine. Currently serving as VP of Research & Development at Iksuda Therapeutics, Jutta leads the strategy and implementation of the company’s ADC pipeline, overseeing research, preclinical, and clinical activities for the advancement of novel ADC therapeutic candidates. She began her career in the ADC field at ImmunoGen, where she successfully transitioned multiple compounds into clinical development, including CD38-targeting isatuximab (approved for treating multiple myeloma) and an CD37-targeting ADC, naratuximab emtansine, for the treatment of B-cell malignancies.
Seminars
- Attenuating payload platform toxicities through novel linker design
- Case studies for translatability of glucuronide linker ADC design with different payload classes
- Challenges of ADC toxicity assessment for linker-payloads with novel mechanisms of action
As the ADC field rapidly expands beyond the established topoisomerase-I paradigm into dual-payload constructs, bispecific formats, and entirely novel toxin classes, the safety assessment playbook must evolve. With no historical safety data to rely on and toxicity mechanisms that may be fundamentally different from traditional ADCs, developers face an urgent need to establish new frameworks for predicting and mitigating risk.
Join preclinical safety leaders from biotech and large pharma as they share strategies for de-risking the next generation of ADC innovation by:
- Designing fit-for-purpose toxicology packages for dual-payload ADCs, debating whether standard NHP studies are sufficient to detect additive or synergistic toxicities, and exploring how staggered-dosing studies and payload-selective biomarkers can deconvolute the contribution of each warhead to the overall safety profile
- Assessing the unique liabilities of bispecific and biparatopic formats, discussing how altered binding avidity, internalization kinetics, and tissue distribution create novel safety challenges that require bespoke in vitro and in vivo models to accurately predict clinical risk
- Prioritizing novel payload classes by mechanistic profiling, evaluating how a standardized preclinical safety screening cascade, encompassing human primary cell panels, tissue organoids, and computational modelling, can rapidly identify the most promising payloads with differentiated toxicity profiles before committing to costly IND-enabling studies
